Premium
Take of rhesus‐human reassortant tetravalent rotavirus vaccine in breast‐fed infants
Author(s) -
Ceyhan Mehmet,
Kanra Güler,
Seçmeer Gülten,
Midthun Karen,
Davidson Bruce L,
Zito Edward T,
Vesikari Timo
Publication year - 1993
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1993.tb12646.x
Subject(s) - medicine , immunogenicity , rotavirus , breast milk , breast feeding , titer , vaccination , virology , diarrhea , rotavirus vaccine , antibody , immunology , pediatrics , biology , biochemistry
Rhesus‐human reassortant tetravalent rotavirus vaccine at a titer of 4 x 10 4 plaque forming units was evaluated for immmunogenicity in 194 6–8‐week‐old breast‐fed Turkish infants. The vaccine was administered orally as a single dose following either a meal of breast milk or 30 ml of sodium bicarbonate‐buffered soy milk formula. Four‐fold or greater responses in rotavirus IgA ELISA antibody were detected in 62% and 65′% of the infants in the two groups, respectively ( p = 0.62). In a smaller comparison group of non‐breast‐fed infants, an IgA response was detected in 7 of 11 (64%) cases. In all vaccinees, a serological response was detected in 72% of the initially seronegative and 47% of the initially seropositive infants ( p = 0.001). We conclude that the take of rhesus‐human reassortant tetravalent rotavirus vaccine in breast‐fed infants is not compromised by breast feeding before vaccination. However, a higher titered preparation of the same vaccine may be required to improve overall immunogenicity in young infants, particularly in those with pre‐vaccination rotavirus antibody.